115 related articles for article (PubMed ID: 12591389)
1. Posttransplantation Kaposi sarcoma-experience in a patient receiving FK-506 and MMF.
Chiang Y; Chu S; Chuang C
Transplant Proc; 2003 Feb; 35(1):258. PubMed ID: 12591389
[No Abstract] [Full Text] [Related]
2. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group.
Stratta RJ
Transplant Proc; 1997; 29(1-2):654-5. PubMed ID: 9123463
[No Abstract] [Full Text] [Related]
3. Rapidly progressive infiltrated plaques in a transplant recipient.
Salgüero Fernández I; ALfageme Roldán F; Suarez Massa D; Roustan Gullón G
Actas Dermosifiliogr; 2017 Apr; 108(3):255-256. PubMed ID: 27677210
[No Abstract] [Full Text] [Related]
4. Kaposi's sarcoma in the early post-transplant period in a kidney transplant recipient.
Ercan Z; Demir ME; Merhametsiz O; Yayar O; Ulas T; Ayli MD
Nefrologia; 2013 Nov; 33(6):861-2. PubMed ID: 24241380
[No Abstract] [Full Text] [Related]
5. Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications.
Herrero JC; Andrés A; Leiva O; Diaz R; Polo G; Aguirre F; Villacampa F; Rodicio JL; Gonzalez E; Morales JM; Praga M
Transplant Proc; 2002 Feb; 34(1):96. PubMed ID: 11959201
[No Abstract] [Full Text] [Related]
6. No recurrence of Kaposi's sarcoma in a case of renal retransplantation under a calcineurin inhibitor free immunosuppressive regimen: first report.
Segoloni GP; Giraudi R; Messina M; Rossetti M; Biancone L; Leonardi G; Piccoli GB; Magnano A; Gai M
Transpl Int; 2007 Apr; 20(4):395-6. PubMed ID: 17326783
[No Abstract] [Full Text] [Related]
7. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
Forsythe J
Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
[No Abstract] [Full Text] [Related]
8. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients.
Zaltzman J; McAlister V; Russell D; Halloran P; Landsberg D; Busque S; Shoker A; Boucher A; Shapiro J; Tchervenkov J; Peets J
Transplant Proc; 2001; 33(1-2):1044-5. PubMed ID: 11267183
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation.
Undre NA; van Hooff J; Christiaans M; Vanrenterghem Y; Donck J; Heeman U; Kohnle M; Zanker B; Land W; Morales JM; Andrés A; Schäfer A; Stevenson P
Transplant Proc; 1998 Jun; 30(4):1299-302. PubMed ID: 9636527
[No Abstract] [Full Text] [Related]
11. The Benelux experience with the combination of tacrolimus and mycophenolate mofetil.
Squifflet JP; Van Hooff JP; Vanrenterghem Y
Transplant Proc; 1999 Nov; 31(7A):72S-74S. PubMed ID: 10576050
[No Abstract] [Full Text] [Related]
12. Kaposi's sarcoma after renal transplantation--disappearance after reduction of immunosuppression and reappearance 7 years later after start of mycophenolate mofetil treatment.
Gómez E; Aguado S; Rodríguez M; Alvarez-Grande J
Nephrol Dial Transplant; 1998 Dec; 13(12):3279-80. PubMed ID: 9870518
[No Abstract] [Full Text] [Related]
13. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept.
Carl S; Dörsam J; Mandelbaum A; Staehler G; Wiesel M
Transplant Proc; 1998 Jun; 30(4):1236-7. PubMed ID: 9636502
[No Abstract] [Full Text] [Related]
14. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction.
Burke GW; Ciancio G; Alejandro R; Roth D; Ricordi C; Tzakis A; Miller J
Transplant Proc; 1998 Jun; 30(4):1544-5. PubMed ID: 9636627
[No Abstract] [Full Text] [Related]
15. FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group.
Mendez R
Transplant Proc; 1998 Jun; 30(4):1287-9. PubMed ID: 9636522
[TBL] [Abstract][Full Text] [Related]
16. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization.
Nakache R; Weinbroum A; Merhav H; Katz P; Kaplan E
Transplant Proc; 2001 May; 33(3):2294-5. PubMed ID: 11377533
[No Abstract] [Full Text] [Related]
17. Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J
Transplant Proc; 1999; 31(1-2):276-7. PubMed ID: 10083106
[No Abstract] [Full Text] [Related]
18. Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group.
Woodle ES; Jordan ML; Facklam D; Shapiro R; Danovitch GM
Transplant Proc; 1998 Jun; 30(4):1297-8. PubMed ID: 9636526
[No Abstract] [Full Text] [Related]
19. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation.
Wang XH; Tang XD; Xu D
Transplant Proc; 2000 Nov; 32(7):1702-3. PubMed ID: 11119899
[No Abstract] [Full Text] [Related]
20. Single-center experience: tacrolimus and mycophenolate mofetil in early stage of kidney transplantation with liver dysfunction.
Liu B; Lin ZB; Zeng FJ; Ming CS; Sha B; Chen ZS; Chen S
Transplant Proc; 2003 Feb; 35(1):273-4. PubMed ID: 12591396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
